XML 47 R37.htm IDEA: XBRL DOCUMENT v3.22.0.1
Summary of Significant Accounting Policies - Additional Information (Detail)
 12 Months Ended
Jun. 16, 2021
USD ($)
Dec. 31, 2021
USD ($)
Segment
Dec. 31, 2020
USD ($)
Apr. 01, 2020
USD ($)
Jan. 01, 2019
USD ($)
Accounting Policy [Line Items]          
Number of operating segment | Segment   1      
Currency translation adjustment       $ 1,300,000  
Highly liquid investment maturity period   three months or less      
Restricted time deposits   $ 2,100,000 $ 2,100,000    
Cash and cash equivalents   $ 171,223,000 678,393,000    
Short term investments maturity   12 months      
Long term Investments Maturity   12 months      
Impairment of long-lived assets   $ 0      
Description of payment term   The period between the transfer of control of the promised goods and when the Company receives payment is based on 60-day payment terms.      
Description of sales return   Distributors can request to return product to the Company only due to quality issues or for product purchased within one year prior to the product’s expiration date.      
Accumulated deficit   $ (1,264,034,000) (974,011,000)    
Accumulated other comprehensive loss   (4,163,000) (4,499,000)    
ASU 2018-02 [Member] | Impact of change in accounting principle upon adoption of ASU 2018-02 [Member]          
Accounting Policy [Line Items]          
Accumulated deficit         $ 600,000
Accumulated other comprehensive loss         (600,000)
Cumulative Effect, Period of Adoption, Adjustment [Member] | ASU 2016-02 [Member]          
Accounting Policy [Line Items]          
Accumulated deficit         $ (8,700,000)
Astellas and AstraZeneca [Member]          
Accounting Policy [Line Items]          
Amount constrained related to drug product shipment   $ 88,800,000      
AstraZeneca Agreements [Member]          
Accounting Policy [Line Items]          
Profit share percent   50.00%      
HiFiBiO Agreement [Member]          
Accounting Policy [Line Items]          
Initial upfront payment $ 25,000,000.0 $ 25,000,000.0      
Maximum additional future option, clinical, regulatory, and commercial milestone payments $ 1,100,000        
HiFiBiO Agreement [Member] | IPR&D Asset [Member]          
Accounting Policy [Line Items]          
Initial upfront payment   60,000,000.0      
HiFiBiO Agreement [Member] | Accrued Liabilities          
Accounting Policy [Line Items]          
Initial upfront payment   $ 35,000,000.0      
Minimum [Member] | Computer Equipment [Member]          
Accounting Policy [Line Items]          
Property and equipment estimated useful life   3 years      
Minimum [Member] | Laboratory Equipment [Member]          
Accounting Policy [Line Items]          
Property and equipment estimated useful life   3 years      
Minimum [Member] | Machinery [Member]          
Accounting Policy [Line Items]          
Property and equipment estimated useful life   3 years      
Minimum [Member] | Furniture and Fixtures [Member]          
Accounting Policy [Line Items]          
Property and equipment estimated useful life   3 years      
Maximum [Member] | Computer Equipment [Member]          
Accounting Policy [Line Items]          
Property and equipment estimated useful life   5 years      
Maximum [Member] | Laboratory Equipment [Member]          
Accounting Policy [Line Items]          
Property and equipment estimated useful life   5 years      
Maximum [Member] | Machinery [Member]          
Accounting Policy [Line Items]          
Property and equipment estimated useful life   5 years      
Maximum [Member] | Furniture and Fixtures [Member]          
Accounting Policy [Line Items]          
Property and equipment estimated useful life   5 years      
Foreign subsidiaries [Member]          
Accounting Policy [Line Items]          
Cash and cash equivalents   $ 91,200,000 $ 66,000,000.0    
Accounts Receivable from Distributors [Member] | Credit Concentration Risk [Member] | Roxadustat [Member]          
Accounting Policy [Line Items]          
Concentration risk, percentage     64.00%